Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Maria Rita, Migliorino"'
Autor:
Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 10033-10042 (2023)
Background: ALK tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and largely improved the survival outcomes of patients with NSCLC harboring ALK rearrangements. Different ALK TKI compounds have demonstrated antitumor activity in th
Externí odkaz:
https://doaj.org/article/54f230401afe47b6b58e03ea5df5f95f
Autor:
Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Daniele Santini, Sebastiano Buti, Olga Nigro, Luca Cantini, Massimo Di Maio, Joachim G. J. V. Aerts, Emilio Bria, Federica Bertolini, Miriam Grazia Ferrara, Michele Ghidini, Francesco Grossi, Annalisa Guida, Rossana Berardi, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Lorenzo Antonuzzo, Alain Gelibter, Paolo Marchetti, Rita Chiari, Marianna Macerelli, Francesca Rastelli, Luigi Della Gravara, Stefania Gori, Alessandro Tuzi, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Pecci, Federica Zoratto, Serena Ricciardi, Maria Rita Migliorino, Francesco Passiglia, Giulio Metro, Gian Paolo Spinelli, Giuseppe L. Banna, Alex Friedlaender, Alfredo Addeo, Corrado Ficorella, Giampiero Porzio, Marcello Tiseo, Marco Russano, Alessandro Russo, David James Pinato
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-f
Externí odkaz:
https://doaj.org/article/ef36c449c9224564a2852f68941a9276
Autor:
Alessio Cortellini, Andrea De Giglio, Katia Cannita, Diego L. Cortinovis, Robin Cornelissen, Cinzia Baldessari, Raffaele Giusti, Ettore D'Argento, Francesco Grossi, Matteo Santoni, Annamaria Catino, Rossana Berardi, Vincenzo Sforza, Giovanni Rossi, Lorenzo Antonuzzo, Vincenzo Di Noia, Diego Signorelli, Alain Gelibter, Mario Alberto Occhipinti, Alessandro Follador, Francesca Rastelli, Rita Chiari, Luigi Della Gravara, Alessandro Inno, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Michele Montrone, Fabrizio Citarella, Maria Vittoria Pensieri, Marco Russano, Luca Cantini, Olga Nigro, Alessandro Leonetti, Paola Bordi, Gabriele Minuti, Lorenza Landi, Alessandro De Toma, Clelia Donisi, Serena Ricciardi, Maria Rita Migliorino, Valerio Maria Napoli, Gianmarco Leone, Giulio Metro, Giuseppe L. Banna, Alex Friedlaender, Alfredo Addeo, Corrado Ficorella, Giampiero Porzio
Publikováno v:
Thoracic Cancer, Vol 12, Iss 6, Pp 880-889 (2021)
Abstract Background Improved outcome in tobacco smoking patients with non‐small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first‐line immunotherapy in
Externí odkaz:
https://doaj.org/article/c7f53a01da6942bfa7ce73222085c5cd
Autor:
Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro’, Federico Cappuzzo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sens
Externí odkaz:
https://doaj.org/article/2272c4a411464ed7ab0c54c8cd9b40b4
Autor:
Alessio Cortellini, Sebastiano Buti, Melissa Bersanelli, Raffaele Giusti, Fabiana Perrone, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Antonino Grassadonia, Katia Cannita, Alessandra Tessitore, Federica Zoratto, Enzo Veltri, Francesco Malorgio, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Gian Carlo Antonini Cappellini, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Federica Pergolesi, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Daniela Iacono, Maria Rita Migliorino, Alain Gelibter, Mario Alberto Occhipinti, Francesco Martella, Alessandro Inno, Stefania Gori, Sergio Bracarda, Cristina Zannori, Claudia Mosillo, Alessandro Parisi, Giampiero Porzio, Domenico Mallardo, Maria Concetta Fargnoli, Marcello Tiseo, Daniele Santini, Paolo A Ascierto, Corrado Ficorella
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cance
Externí odkaz:
https://doaj.org/article/4699db3802134eacb6e95731df7e4bdc
Autor:
Sai-Hong Ignatius, Ou, Makoto, Nishio, Myung-Ju, Ahn, Tony, Mok, Fabrice, Barlesi, Caicun, Zhou, Enriqueta, Felip, Filippo, de Marinis, Sang-We, Kim, Maurice, Pérol, Geoffrey, Liu, Maria Rita, Migliorino, Dong-Wan, Kim, Silvia, Novello, Alessandra, Bearz, Pilar, Garrido, Julien, Mazieres, Alessandro, Morabito, Huamao M, Lin, Hui, Yang, Huifeng, Niu, Pingkuan, Zhang, Edward S, Kim
Publikováno v:
Scientia
Circulating tumor DNA; Non–small cell lung cancer; Tumor biomarker ADN tumoral circulante; Cáncer de pulmón de células no pequeñas; Biomarcador tumoral ADN tumoral circulant; Càncer de pulmó de cèl·lules no petites; Biomarcador tumoral Intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7948bf1ff461e62f90cbe6656037f9
https://doi.org/10.1016/j.jtho.2022.08.018
https://doi.org/10.1016/j.jtho.2022.08.018
Autor:
Paolo Bironzo, Laura Melocchi, Valentina Monica, Dario Trebeschi, Fausto Barbieri, Evaristo Maiello, Maria Rita Migliorino, Alessandra Lombardi, Marcello Tiseo, Luisella Righi, Paolo Graziano, Giulio Rossi, Silvia Novello
Publikováno v:
Pathologica. 114:278-287
37 ALK FISH-positive NSCLC cases diagnosed between 2010 and 2015 in 7 Italian centres were investigated with ICH using three different anti-ALK antibodies (ALK1, 5A4 and D5F3). Staining for ALK1 and 5A4 was graded as 0+,1+,2+, and 3+, while the scori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd6e94d32fa0fdd92511bdc0310d2cc
https://doi.org/10.32074/1591-951x-756
https://doi.org/10.32074/1591-951x-756
Autor:
Maria Pia Fuggetta, Maria Rita Migliorino, Serena Ricciardi, Giorgia Osman, Daniela Iacono, Alvaro Leone, Alessandra Lombardi, Giampietro Ravagnan, Stefania Greco, Daniele Remotti, Maria Concetta Pucci Romano
Publikováno v:
Scientifica, Vol 2019 (2019)
Background. Severe skin rash is listed among important side effects of EGFR tyrosine kinase inhibitors. Polydatin (PD), a glycosylated polyphenol, is endowed with anti-inflammatory activity in human epidermal keratinocytes. Objective. This study eval
Externí odkaz:
https://doaj.org/article/a620d988d69c4481bcd914c20b0fbaed
Autor:
Angela Märten, Min Ki Lee, C. Escriu, Nicolas Girard, H. Daoud, Shin Yup Lee, Sanjay Popat, Maximilian Hochmair, Seung Hyeun Lee, Satoru Miura, Hyun Ae Jung, Yong Chul Lee, Maria Rita Migliorino
Publikováno v:
Lung Cancer. 162:9-15
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However, optimal sequence of treatment has yet to be defined. Overall survival (O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4b85188b336a51de07f78a2a92bda3
https://doi.org/10.1016/j.lungcan.2021.09.009
https://doi.org/10.1016/j.lungcan.2021.09.009
Autor:
Giampiero Porzio, Luigi Della Gravara, Carlo Genova, Danilo Rocco, Luca Cantini, Sebastiano Buti, Sergio Bracarda, Marco Filetti, Alessandro Tuzi, R. Bisonni, Giulio Metro, Claudia Bareggi, Francesco Grossi, Francesca Mazzoni, Alfredo Addeo, David J. Pinato, Emilio Bria, Giovanni Mansueto, Vincenzo Adamo, Joachim G.J.V. Aerts, Raffaele Giusti, Diego Signorelli, Alessio Cortellini, Miriam Grazia Ferrara, Giorgia Guaitoli, Lorenza Landi, Corrado Ficorella, Gabriele Minuti, Fabiana Perrone, Fabrizio Citarella, Melissa Bersanelli, Giuseppe Luigi Banna, Emanuela Olmetto, Marina Chiara Garassino, Marco Siringo, Alain Gelibter, Michele De Tursi, Marco Russano, Giulia Mazzaschi, Gian Paolo Spinelli, Vincenzo Sforza, Luca Carmisciano, Rita Chiari, Katia Cannita, Fabrizio Tabbò, Diego Cortinovis, Alessandro De Toma, Serena Ricciardi, Stefania Gori, Olga Nigro, Mariangela Torniai, Rossana Berardi, Marcello Tiseo, Maria Rita Migliorino, Fausto Barbieri, Alessandro Follador, Alessandro Russo, Massimo Di Maio, Pietro Di Marino, Alex Friedlaender, Federica Zoratto
Publikováno v:
European Journal of Cancer, 150, 224-231. Elsevier Ltd.
Background: We previously demonstrated the cumulative poor prognostic role of concomitant medications on the clinical outcome of patients with advanced cancer treated with immune checkpoint inhibitors, creating and validating a drug-based prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f064f47ad0d04a4c5a32c0434d5b0ba1
https://doi.org/10.1016/j.ejca.2021.03.041
https://doi.org/10.1016/j.ejca.2021.03.041